News & Insights

Pharmacy Monitoring: Why Real-Time Visibility Beats Reactive Audits

InfinityRx — Thu, 16 Jul 2026 17:20:21 GMT

A pharmacy starts concentrating refills in your program. Benefit design is tightening around accumulators, and copay applications are clustering in ways that shouldn't happen. But none of it shows up on your reports until three weeks later, when the quarterly audit comes back, and by then the pattern has already run through two more claim cycles. The question worth asking is whether this is happening in your programs right now. It probably is. The harder question is whether you can prove it while there's still time to do something about it.

InfinityRx Wins Gold at the 2026 American Business Awards® for Health and Pharmaceutical Services

InfinityRx — Thu, 23 Apr 2026 13:00:00 GMT

InfinityRx Wins Gold at the 2026 American Business Awards® for Health and Pharmaceutical Services

FOR IMMEDIATE RELEASE

Westbury, NY — April 30, 2026 — InfinityRx has been named a Gold Stevie® Award Winner in the Health and Pharmaceutical Services category at the 24th Annual American Business Awards®. The recognition marks the company's second Gold Stevie® and its third consecutive year of Stevie® recognition, following a Gold win in 2024 and a Bronze in 2025.

Unified Dual Benefit: Why Pharmacy and Medical Belong on One Platform

InfinityRx — Sun, 19 Apr 2026 13:00:00 GMT

Every specialty brand manager who's been in the role for more than a year has felt this: your drug flows across two different benefit types, and the operational overhead of reconciling them is higher than it should be.

One vendor handles pharmacy benefit copay. A different vendor handles medical benefit claims. The two systems were built by different teams, on different technology, with different data, different implementation timelines, and different business logic. Neither one can answer a question about the other. Your finance team spends the first week of every month building the reconciliation.

This isn't a new problem. But it's worth asking whether it has to be a permanent one.

Under-Reimbursement: The Gross-to-Net Leak Most Manufacturers Don't See

InfinityRx — Sun, 19 Apr 2026 11:00:00 GMT

Copay accumulator and maximizer defense gets most of the air in the patient support conversation, and reasonably so — the dollar magnitude is enormous and the visibility is high. But there's a quieter threat to manufacturer economics that rarely gets quantified in the same conversation, and for some specialty brands it's nearly as large.

Under-reimbursement.

The mechanics are simple. When a pharmacy dispenses a specialty drug, it's reimbursed at a rate determined by the payer — the plan, the PBM, or (in manufacturer copay programs) the copay program itself. That rate is supposed to cover the pharmacy's acquisition cost plus a reasonable dispensing margin. Sometimes it doesn't. When the pharmacy's acquisition cost is higher than the reimbursement it receives, the pharmacy takes a loss on the dispense. Pharmacies don't take losses on dispenses forever.

InfinityRx Awarded Two Platinum and Two Gold Honors at the 2026 TITAN Business Awards

InfinityRx — Sat, 18 Apr 2026 13:00:00 GMT

InfinityRx has been recognized at the 2026 TITAN Business Awards: Season 1 with four honors across the Business Development category for its submission Reshape the Future of Patient Support.

InfinityRx CEO Greg Savino Recognized at the 2026 Noble Business Awards

InfinityRx — Sun, 12 Apr 2026 13:00:00 GMT

Westbury, NY — April 30, 2026 — The 2026 Noble Business Awards has officially revealed its winners for Season 1, recognizing distinguished leaders, forward-thinking organizations, and high-performing enterprises that exemplify excellence in global business.

InfinityRx Named #2 Fastest-Growing Company in the Northeast on the 2026 Inc. Regionals List

InfinityRx — Sat, 04 Apr 2026 13:00:00 GMT

Westbury, NY — March 15, 2026 — InfinityRx has been named #2 on the 2026 Inc. Regionals Northeast list, ranking among the fastest-growing private companies in the region. The recognition reflects InfinityRx's revenue trajectory since its founding in 2021 and its expanding footprint in pharmaceutical patient support services.

Speed as a Strategy: What 1 to 2 Week Launches Mean for Your Portfolio

InfinityRx — Sat, 04 Apr 2026 13:00:00 GMT

Implementation speed in patient support gets reported as a project-management number. The conversation usually sounds like this: legacy implementations take 3 to 6 months, sometimes longer; integrating a hub, an adjudicator, a PBM relationship, a defense vendor, a reporting tool, and a patient engagement layer is operationally complex; that complexity drives the timeline.

That framing is correct, and incomplete. The thing it leaves out: every quarter your program isn't live is a quarter of accumulator exposure, maximizer exposure, and under-reimbursement you're not defending. Speed of implementation is not an operational metric. It is, in 2026, a GTN metric.

Here's why the math matters, and what changes when implementation drops from quarters to weeks.

Program Leakage: A Closed-Loop Framework for Recovery and Prevention

InfinityRx — Sat, 04 Apr 2026 13:00:00 GMT

A note about language, and why it matters.

The vocabulary around program integrity in patient support has historically borrowed from fraud investigation. "Fraud, waste, and abuse" (FWA) is the shorthand carried over from Medicare/Medicaid integrity programs. "Fraud detection" is the label most vendors still use on their analytics packages.

That vocabulary creates two problems. The first is legal: manufacturer patient support programs are commercial contracts, not government benefits. Accusing a pharmacy, prescriber, or patient of "fraud" based on statistical pattern detection is a serious claim with evidentiary requirements most programs can't meet. The second is operational: the fraud framing implies an adversarial posture toward pharmacies and providers that a manufacturer doesn't actually want — because those same pharmacies and providers are the distribution pathway for the drug.

There's a better vocabulary. It's more precise, more defensible, and more aligned with what the work actually is.

Maximizers: The Quieter, More Expensive Threat to Your Copay Program

InfinityRx — Wed, 25 Mar 2026 13:00:00 GMT

Accumulators get most of the airtime in the manufacturer copay conversation. Maximizers, in 2026, are the more expensive design.

Industry analysts, including Drug Channels Institute, consistently flag maximizer adoption as the faster-growing of the two designs, and the more economically punishing for manufacturers per affected patient. The mechanism is more subtle than an accumulator, the design is harder to identify from claims data, and a meaningful percentage of every dollar that flows through the maximizer is captured by the maximizer vendor as a fee.

Here is how the design works, why it has been growing faster than accumulators, and what manufacturers are doing about it now.